Advances in understanding the tumor microenvironment of neuroendocrine prostate cancer
Longitudinal biopsies, spatial multi-omics, humanized models and biomarker-defined trials are needed to distinguish causal vulnerabilities from correlates of treatment-emergent lineage transition.